Cargando…
An unexpected turn of fortune: targeting TRAIL-Rs in KRAS-driven cancer
Twenty-one percent of all human cancers bear constitutively activating mutations in the proto-oncogene KRAS. This incidence is substantially higher in some of the most inherently therapy-resistant cancers including 30% of non-small cell lung cancers (NSCLC), 50% of colorectal cancers, and 95% of pan...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7078304/ https://www.ncbi.nlm.nih.gov/pubmed/32194994 http://dx.doi.org/10.1038/s41420-020-0249-4 |